CSL:ASXCSL Limited Analysis

CSL Limited is trading at A$99.76, comfortably above its 20‑day SMA (111.87) and well below its 200‑day SMA (173.39), signaling a persistent bearish trend. Technical indicators are weak: the 14‑day RSI sits at 22.7 (deeply oversold), the MACD line is below its signal line, and the price is hovering near the identified support of A$93.64 with resistance at A$132.21. Recent material news highlights a sweeping guidance downgrade, a multi‑billion‑dollar asset write‑down, and a restructuring plan that includes spinning off the Seqirus business and closing plasma collection centres, all of which have pressured the share price to multi‑year lows.
Despite these headwinds, CSL’s valuation appears mixed: a trailing P/E of 11.6 is well under the industry average of 27.6, and the dividend yield of 4.27% is attractive, yet the DCF‑derived fair value of A$29.35 suggests the market is pricing in significant risk. The company generates solid operating cash flow (A$3.6 bn) and free cash flow (A$1.85 bn) with a payout ratio below 50%, indicating dividend sustainability.
Looking forward, analysts project a median target price of A$151.25, implying roughly 50% upside, but the high 30‑day volatility (≈55%) and a historic max drawdown of 64% underscore the uncertainty. Investors should weigh the strong dividend and relative valuation discount against the ongoing operational challenges and elevated short‑term risk.